Covid-19 roundup: Operation Warp Speed's 7th vaccine is live attenuated; Small biotech touts big success where giants have failed
Operation Warp Speed is stacking its vaccine portfolio with a “TBD” new candidate: a live attenuated vaccine that can be administered in a single dose, potentially as an oral formulation rather than an injection.
That could be because the unannounced candidate appears to match the profile of an inoculation being developed by Merck, according to Bloomberg, which first reported the development based on a presentation by Moncef Slaoui.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,000+ biopharma pros reading Endpoints daily — and it's free.